Bryan T. Vaughn
Known title: EVP, DiagnosticsCIK: 0002103999
Associated companies
Transaction History
| LH | ▼ Sell | Open Market | 234 | $67K | 7/2/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 93 | $26K | 7/1/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 327 | — | 7/1/2026 | View on chart |
| LH | ▲ Buy | Grant | 1,584 | $0 | 3/26/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 451 | $121K | 3/26/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 323 | — | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 93 | $27K | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 61 | $17K | 2/9/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 178 | — | 2/7/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 180 | — | 2/6/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 61 | $17K | 2/6/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.